Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction
-
Published:2024-09
Issue:11
Volume:84
Page:1041-1045
-
ISSN:0735-1097
-
Container-title:Journal of the American College of Cardiology
-
language:en
-
Short-container-title:Journal of the American College of Cardiology
Author:
Desai Milind Y., Owens Anjali, Wolski Kathy, Geske Jeffrey B., Saberi Sara, Wang Andrew, Sherrid MarkORCID, Cremer Paul C., Lakdawala Neal K., Tower-Rader Albree, Fermin David, Naidu Srihari S., Smedira Nicholas G., Schaff Hartzell, McErlean Ellen, Sewell Christina, Zhong Yue, Wyrwich Kathleen W., Lampl Kathy L., Sehnert Amy J., Nissen Steven E., Spertus John A.
Funder
Bristol-Myers Squibb Co
Reference10 articles.
1. Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy;Nassif;JACC Heart Fail,2022 2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial;Olivotto;Lancet,2020 3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial;Spertus;Lancet,2021 4. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy;Desai;J Am Coll Cardiol,2022 5. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks;Desai;Circulation,2023
|
|